SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) · doi:10.1101/2021.01.15.426911 · Cited by 1,354

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human seraPreprint

Rathnasinghe, R., Jangra, S., Čupić, A., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., Mena, I., Vrieze, J. D., et al. (2021) · medRxiv · doi:10.1101/2021.01.19.21249592 · Cited by 110

Detection and evolution of SARS-CoV-2 coronavirus variants of concern with mass spectrometry

Mann, C., Griffin, J. H., & Downard, K. M. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03649-1 · Cited by 28

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

Barreiro, A., Prenafeta, A., Bech-Sabat, G., Roca, M., Perozo Mur, E., March, R., González-González, L., Madrenas, L., Corominas, J., Fernández, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106126 · Cited by 28

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2

Wang, R., Zhang, Q., Zhang, R., Aw, Z. Q., Chen, P., Wong, Y. H., Hong, J., Ju, B., Shi, X., Ding, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.854952 · Cited by 29

Emergence of COVID-19 Variants: An Update

Gupta, P., Gupta, V., Singh, C. M., & Singhal, L. (2023) · Cureus · doi:10.7759/cureus.41295 · Cited by 34

Sensitive Detection of SARS-CoV-2 Spike Protein Using an Aptamer Sandwich Assay-Based Electrochemical Biosensor

Kim, H.-M., & Park, J. (2024) · BioChip Journal · doi:10.1007/s13206-024-00174-y · Cited by 28

Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2)

Istıflı, E. S., Netz, P. A., Tepe, A. S., Sarıkürkçü, C., & Tepe, B. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1975569 · Cited by 24

Genetic drift in the genome of SARS COV‐2 and its global health concern

Bano, I., Sharif, M., & Alam, S. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27337 · Cited by 23

Molecular Insights into the Differential Dynamics of SARS-CoV-2 Variants of Concern (VOC)

Mandal, N., Padhi, A. K., & Rath, S. L. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2022.108194 · Cited by 28

Effects of epistasis and recombination between vaccine-escape and virulence alleles on the dynamics of pathogen adaptation

McLeod, D. V., & Gandon, S. (2022) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01709-y · Cited by 26

SARS-COV-2 RBD (Receptor binding domain) mutations and variants (A sectional-analytical study)

Hajizadeh, F., Khanizadeh, S., Khodadadi, H., Mokhayeri, Y., Ajorloo, M., Malekshahi, A., & Heydari, E. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105595 · Cited by 26

Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 spike Mutations Associated with Variants of Concern

Babiker, A., Immergluck, K., Stampfer, S. D., Rao, A., Bassit, L., Su, M., Nguyen, V., Stittleburg, V. D., Ingersoll, J., Bradley, H. L., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01446-21 · Cited by 26

Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies

Fernández, J., Bruneau, N., Fasce, R., Martín, H. S., Balanda, M., Bustos, P., Ulloa, S., Mora, J., & Ramírez, E., V (2021) · Journal of Medical Virology · doi:10.1002/jmv.27310 · Cited by 25

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

Bayarri‐Olmos, R., Jarlhelt, I., Johnsen, L. B., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Matthiesen, F., Nielsen, S. D., Iversen, K. K., Ostrowski, S. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757197 · Cited by 25

Variants of SARS-CoV-2: Influences on the Vaccines’ Effectiveness and Possible Strategies to Overcome Their Consequences

Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26

Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity

Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27

Improved neutralisation of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech (BNT162b2) COVID-19 vaccine boosting with a third dosePreprint

Basile, K., Rockett, R. J., McPhie, K. A., Fennell, M., Johnson-Mackinnon, J. C., Agius, J. E., Fong, W., Rahman, H., Ko, D., Donavan, L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.12.472252 · Cited by 25

Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees

Garziano, M., Utyro, O., Poliseno, M., Santantonio, T. A., Saulle, I., Strizzi, S., Caputo, S. L., Clerici, M., Introini, A., & Biasin, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.820250 · Cited by 23

Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants

Chaudhari, A. M., Joshi, M. N., Kumar, D., Patel, A., Lokhande, K. B., Krishnan, A., Hanack, K., Filipek, S., Liepmann, D., Renugopalakrishnan, V., et al. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.08.010 · Cited by 24

The R203M and D377Y mutations of the nucleocapsid protein promote SARS-CoV-2 infectivity by impairing RIG-I-mediated antiviral signaling

Li, Y., Li, M., Xiao, H., Liao, F., Shen, M., Ge, W.-W., Ou, J., Liu, Y., Chen, L.-M., Zhao, Y., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012886 · Cited by 16

An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research

Yang, P., Yang, Y., Wu, Y., Huang, C., Ding, Y., Wang, X., & Wang, S. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114221 · Cited by 23

An overview of the ongoing challenges in SARS-CoV-2 global control

Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24

Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2)

Xiang, Y., Wang, M., Chen, H., & Chen, L. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114724 · Cited by 24

Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India

Singh, P., Sharma, K. K., Singh, P., Bhargava, A., Negi, S. S., Sharma, P., Bhise, M. P., Tripathi, M. K., Jindal, A., & Nagarkar, N. M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105404 · Cited by 22

E156G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.617.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escapePreprint

Chaudhari, A. M., Kumar, D., Joshi, M. N., Patel, A. K., & Joshi, C. G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.07.447321 · Cited by 22

Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan

Furukawa, K., Tjan, L. H., Sutandhio, S., Kurahashi, Y., Iwata, S., Tohma, Y., Sano, S., Nakamura, S., Nishimura, M., Arii, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab430 · Cited by 22

New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil

Goes, L. R., Siqueira, J. D., Garrido, M. M., Alves, B. M., Pereira, A. C. P. M., Cicala, C., Arthos, J. A., Viola, J. P. B., & Soares, M. A. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104998 · Cited by 21

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21

Fast detection of SARS-CoV-2 variants including Omicron using one-step RT-PCR and Sanger sequencing

Bloemen, M., Rector, A., Swinnen, J., Ranst, M. A. V., Maes, P., Vanmechelen, B., & Wollants, E. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2022.114512 · Cited by 20

Identification of herbal teas and their compounds eliciting antiviral activity against SARS-CoV-2 in vitro

Le‐Trilling, V. T. K., Mennerich, D., Schuler, C., Sakson, R., Lill, J. K., Kasarla, S. S., Kopczynski, D., Loroch, S., Flores-Martinez, Y., Katschinski, B., et al. (2022) · BMC Biology · doi:10.1186/s12915-022-01468-z · Cited by 21

Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants

Snell, L. B., Cliff, P. R., Charalampous, T., Alcolea-Medina, A., Ebie, S. A. R. T., Sehmi, J. K., Flaviani, F., Batra, R., Douthwaite, S. T., Edgeworth, J. D., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00482-5 · Cited by 20

Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures

Arévalo, S. J., Sifuentes, D. Z., Huallpa, C. J., Bianchi, G. L., Chávez, A. C., Casas, R. G.-S., Calampa, C. S. U., Uceda-Campos, G., & Pineda, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-97267-7 · Cited by 22

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

Song, S., Zhou, B., Cheng, L., Liu, W., Fan, Q., Ge, X., Peng, H., Fu, Y., Ju, B., & Zhang, Z. (2022) · Virology Journal · doi:10.1186/s12985-021-01737-3 · Cited by 19

Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction

Chaudhari, A. M., Singh, I., Joshi, M. N., Patel, A. K., & Joshi, C. G. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10405-9 · Cited by 20

Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds

Cantoni, D. M., Neto, M. M., Nadesalingam, A., Wells, D. A., Carnell, G., Ohlendorf, L., Ferrari, M., Palmer, P., Chan, A. C. Y., Smith, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.773982 · Cited by 20

SARS-CoV-2 shedding dynamics and transmission in immunosuppressed patients

Lee, J., Yun, K. W., Jeong, H., Kim, B., Kim, M. J., Park, J. H., Shin, H. S., Oh, H. S., Sung, H., Song, M. G., et al. (2022) · Virulence · doi:10.1080/21505594.2022.2101198 · Cited by 18

Host Membranes as Drivers of Virus Evolution

Matveeva, M., Lefebvre, M., Chahinian, H., Yahi, N., & Fantini, J. (2023) · Viruses · doi:10.3390/v15091854 · Cited by 20

Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021

Lassaunière, R., Polacek, C., Fonager, J., Bennedbæk, M., Boding, L., Rasmussen, M., & Fomsgaard, A. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.49.2101059 · Cited by 19

Human-to-dog transmission of SARS-CoV-2, Colombia

Rivero, R., Garay, E., Botero, Y., Coll, H. A. S., Gastelbondo, B., Muñoz, M., Ballesteros, N., Castañeda, S., Patiño, L. H., Ramírez, J. D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11847-9 · Cited by 20

Protective Effect Conferred by Prior Infection and Vaccination on COVID-19 in a Healthcare Worker Cohort in South India

Murugesan, M., Mathews, P., Paul, H. E., Rajiv Karthik, K., Mammen, J., & Rupali, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0268797 · Cited by 24

Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteins—A Possible Signature of Adaptive Selection

Alisoltani, A., Jaroszewski, L., Iyer, M., Iranzadeh, A., & Godzik, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.875406 · Cited by 20

Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination

Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages

Yang, H. J., He, X., Shi, H., He, C., Hong, L., He, H., Yang, L., Wang, W., Shen, G., Yang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02139-5 · Cited by 23

The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model

Cochin, M., Lucıanı, L., Touret, F., Driouich, J., Petit, P.-R., Moureau, G., Baronti, C., Laprie, C., Thirion, L., Maes, P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03171-9 · Cited by 17

SARS-CoV-2: The Interplay Between Evolution and Host Immunity

Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 26

Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity

Schetelig, J., Heidenreich, F., Baldauf, H., Trost, S., Falk, B., Hoßbach, C., Real, R. G. L., Roers, A., Lindemann, D., Dalpke, A. H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698193 · Cited by 18

Introduction and rapid dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela

Jaspe, R., Loureiro, C., Sulbarán, Y., Moros, Z., D'Angelo, P., Rodríguez, L., Zambrano, J. L., Hidalgo, M., Vizzi, E., Alarcón, V., et al. (2021) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2021.105147 · Cited by 13

Severe Acute Respiratory Syndrome Type 2‐Causing Coronavirus: Variants and Preventive Strategies

Aydoğdu, M. O., Rohn, J. L., Jafari, N. V., Brako, F., Homer‐Vanniasinkam, S., & Edirisinghe, M. J. (2022) · Advanced Science · doi:10.1002/advs.202104495 · Cited by 18

Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota

Petrone, M. E., Rothman, J. E., Breban, M. I., Ott, I. M., Russell, A., Lasek‐Nesselquist, E., Badr, H. S., Kelly, K., Omerza, G., Renzette, N., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03347-3 · Cited by 17

Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron

Yu, C. Y., Wong, S. Y., Liew, N. W. C., Joseph, N. M. S., Zakaria, Z., Isa, N. M., Soe, H. J., Kairon, R., Nordin, S. A., & Chee, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1001022 · Cited by 19

Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity

Williams, J. A., Biancucci, M., Lessen, L. N., Tian, S., Balsaraf, A., Chen, L., Chesterman, C. C., Maruggi, G., Vandepaer, S., Huang, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg0330 · Cited by 18

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants

Haycroft, E. R., Davis, S. K., Ramanathan, P., López, E., Purcell, R. A., Tan, L. L., Pymm, P., Wines, B. D., Hogarth, P. M., Wheatley, A. K., et al. (2023) · Medical Microbiology and Immunology · doi:10.1007/s00430-023-00773-w · Cited by 21

Zoonosis and zooanthroponosis of emerging respiratory viruses

Khalil, A. M., Martínez‐Sobrido, L., & Mostafa, A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1232772 · Cited by 25

COVID-19 Variants and Vaccine Development

Zhao, Z., Bashiri, S., Ziora, Z. M., Tóth, I., & Skwarczyński, M. (2024) · Viruses · doi:10.3390/v16050757 · Cited by 20

Targeting SARS-CoV-2 Receptor Binding Domain with Stapled Peptides: An In Silico Study

de Campos, L. J., Palermo, N. Y., & Conda‐Sheridan, M. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c02398 · Cited by 16

Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh

Ahammad, I., Hossain, M. U., Rahman, A., Chowdhury, Z. M., Bhattacharjee, A., Das, K. C., Keya, C. A., & Salimullah, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258019 · Cited by 17

Advancements in Testing Strategies for COVID-19

Asghar, R., Rasheed, M., Hassan, J. U., Rafique, M., Khan, M., & Deng, Y. (2022) · Biosensors · doi:10.3390/bios12060410 · Cited by 17

Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design

Bagherzadeh, M. A., Izadi, M., Baesi, K., Jahromi, M. A. M., & Pirestani, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-18152-5 · Cited by 17

N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody

Zibat, A., Zhang, X., Dickmanns, A., Stegmann, K. M., Dobbelstein, A. W., Alachram, H., Soliwoda, R., Salinas, G., Groß, U., Görlich, D., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107786 · Cited by 16

COVID-19 mutations: An overview

Sarkar, M. S., & Madabhavi, I. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i3.89761 · Cited by 22

Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing

Lhomme, S., Latour, J., Jeanne, N., Trémeaux, P., Ranger, N., Migueres, M., Salin, G., Donnadieu, C., & Izopet, J. (2021) · Viruses · doi:10.3390/v13122544 · Cited by 16

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies

Ling, Z., Yi, C., Sun, X., Yang, Z., & Sun, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2215-6 · Cited by 16

Association of SARS-CoV-2 Nucleocapsid Protein Mutations with Patient Demographic and Clinical Characteristics during the Delta and Omicron Waves

Alsuwairi, F. A., Alsaleh, A. N., Alsanea, M. S., Al-Qahtani, A. A., Obeid, D. A., Almaghrabi, R. S., Alahideb, B. M., AlAbdulkareem, M. A., Mutabagani, M. S., Althawadi, S., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11051288 · Cited by 16

Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity

Rutten, L., Swart, M., Koornneef, A., Bouchier, P., Blokland, S., Sadi, A., Juraszek, J., Vijayan, A., Schmit-Tillemans, S. P. R., Verspuij, J. W. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-56293-x · Cited by 18

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency

Leach, A., Ilca, F. T., Akbar, Z., Ferrari, M., Bentley, E. M., Mattiuzzo, G., Onuoha, S. C., Miller, A., Ali, H., & Rabbitts, T. H. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105147 · Cited by 16

Rapid Automated Screening for SARS-CoV-2 B.1.617 Lineage Variants (Delta/Kappa) through a Versatile Toolset of qPCR-Based SNP Detection

Nörz, D. S., Grunwald, M., Tang, H. T., Olearo, F., Günther, T., Robitaille, A., Fischer, N., Grundhoff, A. T., Aepfelbacher, M., Pfefferle, S., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11101818 · Cited by 16

Mutation-Induced Long-Range Allosteric Interactions in the Spike Protein Determine the Infectivity of SARS-CoV-2 Emerging Variants

Das, J. K., Thakuri, B., MohanKumar, K., Roy, S., Sljoka, A., Sun, G., & Chakraborty, A. (2021) · ACS Omega · doi:10.1021/acsomega.1c05155 · Cited by 15

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern

Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 16

SARS‐CoV‐2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice

Ma, Y., Wang, Y., Dong, C., Gonzalez, G. X., Zhu, W., Kim, J., Wei, L., Kang, S., & Wang, B. (2022) · Small · doi:10.1002/smll.202200836 · Cited by 14

Cellular senescence as a source of SARS‐CoV‐2 quasispecies

Karakasiliοtis, I., Lаgopati, N., Evangelou, K., & Gorgoulis, V. G. (2021) · FEBS Journal · doi:10.1111/febs.16230 · Cited by 15

An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study

Gil‐Redondo, R., Conde, R., Bizkarguenaga, M., Bruzzone, C., Laín, A., González‐Valle, B., Iriberri, M., Ramos‐Acosta, C., Anguita, E., Lariz, J. I. A., et al. (2022) · Metabolites · doi:10.3390/metabo12121206 · Cited by 15

Mosaic Recombination Inflicted Various SARS-CoV-2 Lineages to Emerge into Novel Virus Variants: a Review Update

Singh, P., Sharma, K. K., Shaw, D., Bhargava, A., & Negi, S. S. (2022) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-022-01109-w · Cited by 15

Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants

Bhattacharya, M., Chatterjee, S., Lee, S., Dhama, K., & Chakraborty, C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101008 · Cited by 16

Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants

Ghildiyal, T., Rai, N., Rawat, J. M., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024) · Journal of Immunology Research · doi:10.1155/2024/9125398 · Cited by 16

Sequencing on an imported case in China of COVID‐19 Delta variant emerging from India in a cargo ship in Zhoushan, China

Wu, B., Zhang, H., Wang, Y., Tang, A., Li, K., Li, P., Chen, J., Wang, H. M., & Yan, J. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27239 · Cited by 14

Natural products as a source of Coronavirus entry inhibitors

Szabó, D., Crowe, A. P., Mamotte, C. D. S., & Strappe, P. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1353971 · Cited by 14

A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug

Liu, Q., Cai, C., 黄燕燕, Zhou, L., Guan, Y., Fu, S., Lin, Y., Yang, T., Yan, H., Zhang, Z., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06802-7 · Cited by 14

Current Updates on Variants of SARS‐CoV‐ 2: Systematic Review

Erkihun, M., Ayele, B., Asmare, Z., & Endalamaw, K. (2024) · Health Science Reports · doi:10.1002/hsr2.70166 · Cited by 16

Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection

Dell’Isola, G. B., Felicioni, M., Ferraro, L., Capolsini, I., Cerri, C., Gurdo, G., Mastrodicasa, E., Massei, M. S., Perruccio, K., Brogna, M., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.712603 · Cited by 11

Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report

Fenaux, H., Gueneau, R., Chaghouri, A., Henry, B., Mouna, L., Roque‐Afonso, A., & Vauloup‐Fellous, C. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06902-1 · Cited by 14

Prediction of Recurrent Mutations in SARS-CoV-2 Using Artificial Neural Networks

Saldivar‐Espinoza, B., Macip, G., Garcia‐Segura, P., Mestres‐Truyol, J., Puigbò, P., Cereto‐Massagué, A., Pujadas, G., & García-Vallvé, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314683 · Cited by 15

The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2

Aliyari, S. R., Quanquin, N. M., Pernet, O., Zhang, S., Wang, L., & Cheng, G. (2022) · Pathogens · doi:10.3390/pathogens11050538 · Cited by 17

Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection

Arriaga-Canon, C., Contreras‐Espinosa, L., Rebollar‐Vega, R., Montiel-Manríquez, R., Cedro‐Tanda, A., García-Gordillo, J. A., Álvarez-Gómez, R. M., Jiménez-Trejo, F. J., Hernández, C. C., & Herrera, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911058 · Cited by 14

A potential allosteric inhibitor of SARS-CoV-2 main protease (Mpro) identified through metastable state analysis

Fatima, A., Geethakumari, A. M., Ahmed, W. S., & Biswas, K. H. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1451280 · Cited by 13

Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine

Lineburg, K. E., Neller, M. A., Ambalathingal, G. R., Texier, L. L., Raju, J., Swaminathan, S., Lekieffre, L., Smith, C., Rehan, S., Crooks, P., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1326 · Cited by 14

Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy

Dorlass, E. G., Lourenço, K. L., Magalhães, R. D. M., Sato, H. I., Fiorini, A., Peixoto, R. B., Coelho, H. P., Telezynski, B. L., Scagion, G. P., Ometto, T., et al. (2021) · Genomics · doi:10.1016/j.ygeno.2021.10.015 · Cited by 13

Large Screening Identifies ACE2 Positively Correlates With NF-κB Signaling Activity and Targeting NF-κB Signaling Drugs Suppress ACE2 Levels

Yan, M., Dong, Y., Bo, X., Cheng, Y., & Cheng, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771555 · Cited by 13

The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution

Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12

Molecular Evolution and Epidemiological Characteristics of SARS COV-2 in (Northwestern) Poland

Serwin, K., Ossowski, A., Szargut, M., Cytacka, S., Urbańska, A., Majchrzak, A., Niedźwiedź, A., Czerska, E., Pawińska-Matecka, A., Gołąb, J., et al. (2021) · Viruses · doi:10.3390/v13071295 · Cited by 12

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chong, Z. X., Liew, W.-P.-P., Ong, H. K., Yong, C. Y., Shit, C. S., Ho, W. Y., Ng, S., & Yeap, S. K. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153565 · Cited by 13

Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy

Zhou, D., Zhou, R., & Chen, Z. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab027 · Cited by 12

Probing the mutational landscape of the SARS-CoV-2 spike protein via quantum mechanical modeling of crystallographic structures

Zaccaria, M., Genovese, L., Dawson, W., Cristiglio, V., Nakajima, T., Johnson, W., Farzan, M., & Momeni, B. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac180 · Cited by 7

Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses

Pacheco-Olvera, D. L., Remy-Hernández, S. S., García-Valeriano, M. G., Rivera-Hernández, T., & López-Macías, C. I. R. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.10.007 · Cited by 12

Nucleocapsid Mutations R203K/G204R Increase the Infectivity, Fitness and Virulence of SARS-CoV-2Preprint

Wu, H., Xing, N., Meng, K., Fu, B., Xue, W., Dong, P., Tang, W., Xiao, Y., Liu, G., Luo, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3896432 · Cited by 12

Designing In-House SARS-CoV-2 RT-qPCR Assay for Variant of Concerns

Ergören, M. Ç., Tuncel, G., Özverel, C. S., & Şanlıdağ, T. (2022) · Global Medical Genetics · doi:10.1055/s-0042-1756660 · Cited by 11

Mutation profile of SARS-CoV-2 genome in a sample from the first year of the pandemic in Colombia

Gálvez, J. M., Chaparro-Solano, H. M., Pinzón-Rondón, Á. M., Albornóz, L. L., Oviedo, J. M. P., Zapata-Gómez, F. A., Patiño-Aldana, A. F., Hernandez-Rodríguez, A. D., Quiroz, M. A. D., & Ruiz-Sternberg, Á. M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105192 · Cited by 11

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

Moros, A., Prenafeta, A., Barreiro, A., Perozo, E., Fernández, A., Cañete, M., González‐González, L., Garriga, C., Pradenas, E., Marfil, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.008 · Cited by 9

Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA

Liu, Y., Dai, L., Feng, X., Gao, R., Zhang, N., Wang, B., Han, J.-B., Zou, Q., Guo, X., Zhu, H., et al. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00054-z · Cited by 11

A SARS-CoV-2: Companion Animal Transmission and Variants Classification

Pandit, R., & Matthews, Q. L. (2023) · Pathogens · doi:10.3390/pathogens12060775 · Cited by 11

Distinct pathways for evolution of enhanced receptor binding and cell entry in SARS-like bat coronaviruses

(2024) · doi:10.1371/journal.ppat.1012704 · Cited by 10

Rapid and accurate identification of SARS-CoV-2 variants containing E484 mutation

Zhang, Y., Wei, Y., Yang, S., Li, Y., Wang, J., Nie, Z., Bi, Y., Liu, W., Wang, L., & Yang, L. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100183 · Cited by 10

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination seraPreprint

Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., PVI study group, Krammer, F., Simon, V. R., Martínez‐Sobrido, L., García‐Sastre, A., & Schotsaert, M. (2021) · medRxiv · doi:10.1101/2021.01.26.21250543 · Cited by 133

Neutralizing response against E484K variant after original SARS-CoV-2 infectionPreprint

Hayashi, T., Yaegashi, N., & Konishi, I. (2021) · medRxiv · doi:10.1101/2021.05.07.21256803

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage

Álvarez-Díaz, D. A., Laiton‐Donato, K., Torres, O., Ruiz-Moreno, H. A., Franco-Muñoz, C., Beltran, M. A., Mercado, M., Rueda, M. G., & Muñoz, A. L. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198629 · Cited by 8

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101